Sunmax Financial Statements From 2010 to 2024

4728 Stock  TWD 278.00  2.00  0.72%   
Sunmax Biotechnology financial statements provide useful quarterly and yearly information to potential Sunmax Biotechnology Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sunmax Biotechnology financial statements helps investors assess Sunmax Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sunmax Biotechnology's valuation are summarized below:
Sunmax Biotechnology Co does not presently have any fundamental trend indicators for analysis.
Check Sunmax Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunmax Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sunmax financial statements analysis is a perfect complement when working with Sunmax Biotechnology Valuation or Volatility modules.
  
This module can also supplement various Sunmax Biotechnology Technical models . Check out the analysis of Sunmax Biotechnology Correlation against competitors.

Sunmax Biotechnology Co Company Current Valuation Analysis

Sunmax Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Sunmax Biotechnology Current Valuation

    
  8.1 B  
Most of Sunmax Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sunmax Biotechnology Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Sunmax Biotechnology Co has a Current Valuation of 8.1 B. This is 43.64% lower than that of the Healthcare sector and 74.27% higher than that of the Biotechnology industry. The current valuation for all Taiwan stocks is 51.3% higher than that of the company.

Sunmax Biotechnology Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Sunmax Biotechnology's current stock value. Our valuation model uses many indicators to compare Sunmax Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sunmax Biotechnology competition to find correlations between indicators driving Sunmax Biotechnology's intrinsic value. More Info.
Sunmax Biotechnology Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.59  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sunmax Biotechnology Co is roughly  1.68 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sunmax Biotechnology's earnings, one of the primary drivers of an investment's value.

About Sunmax Biotechnology Financial Statements

Sunmax Biotechnology investors use historical fundamental indicators, such as Sunmax Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunmax Biotechnology. Please read more on our technical analysis and fundamental analysis pages.

Pair Trading with Sunmax Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sunmax Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sunmax Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving against Sunmax Stock

  0.592881B Fubon Financial HoldingPairCorr
  0.52882 Cathay Financial HoldingPairCorr
  0.462882A Cathay Financial Holding Earnings Call This WeekPairCorr
  0.332330 Taiwan SemiconductorPairCorr
The ability to find closely correlated positions to Sunmax Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sunmax Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sunmax Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sunmax Biotechnology Co to buy it.
The correlation of Sunmax Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sunmax Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sunmax Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sunmax Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Sunmax Stock Analysis

When running Sunmax Biotechnology's price analysis, check to measure Sunmax Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunmax Biotechnology is operating at the current time. Most of Sunmax Biotechnology's value examination focuses on studying past and present price action to predict the probability of Sunmax Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunmax Biotechnology's price. Additionally, you may evaluate how the addition of Sunmax Biotechnology to your portfolios can decrease your overall portfolio volatility.